Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jason Swindle"'
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Outcomes data among patients with heart failure (HF) with reduced ejection fraction treated with sacubitril/valsartan ( SAC / VAL ) are largely limited to clinical trial results. We compared hospitalization and healthcare costs among real
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2809fb233f90e5d7f00365677d7375eb
https://doi.org/10.1161/jaha.118.011089
https://doi.org/10.1161/jaha.118.011089
Objective: To assess real-world costs for patients with hemophilia A treated with bypassing agents versus factor VIII (FVIII) replacement. Methods: Claims data from a large US health insurer during 1 January 2006–30 September 2014 were used for ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6be013bb61b5a169bede5d3c92a3aba9
Publikováno v:
Advances in Therapy. 34:261-276
Prior research suggests increased costs during the final months of life, yet little is known about healthcare cost differences between patients with heart failure (HF) who die or survive. A retrospective claims study from a large US health plan [comm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63c4a0ae43c19e6b3fa129ba205344e1
https://doi.org/10.1007/s12325-016-0454-y
https://doi.org/10.1007/s12325-016-0454-y
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:1446-1456
Heart failure (HF) is a severe chronic disease with growing prevalence and health care burden as well as high mortality. End-of-life cost data for patients with HF may inform disease and medication therapy management.To (a) characterize a real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c22669ea012be5f49021d1aeeba726ba
https://doi.org/10.18553/jmcp.2016.22.12.1446
https://doi.org/10.18553/jmcp.2016.22.12.1446
Publikováno v:
Heart & Lung. 49:211
Background In the PARADIGM-HF trial, sacubitril/valsartan (SAC/VAL) was superior to enalapril in reducing risks of cardiovascular death and heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF); however, there i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afab4e5c7aeb400bd704beed7d2080d8
https://doi.org/10.1016/j.hrtlng.2020.02.012
https://doi.org/10.1016/j.hrtlng.2020.02.012
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 11
Introduction: Among patients with HFrEF, treatment with sacubitril/valsartan (SAC/VAL) was shown in PARADIGM-HF to reduce risks of CV death and HF hospitalization compared with enalapril; however, scarce data exist regarding the impact of SAC/VAL on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b394de6953e2fa4baf0c5871447b76c6
https://doi.org/10.1161/circoutcomes.11.suppl_1.125
https://doi.org/10.1161/circoutcomes.11.suppl_1.125
Publikováno v:
Annals of Pharmacotherapy. 48:847-855
Background:Despite the prevalence of therapies available to patients at highest coronary heart disease risk, only a minority of type 2 diabetes mellitus (T2DM) patients reach desired cholesterol treatment levels, with limited data regarding their out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd3ddd83a8097e77fd8dcb050c2bb11
https://doi.org/10.1177/1060028014531737
https://doi.org/10.1177/1060028014531737
Publikováno v:
Journal of Cardiac Failure. 24:S27
Background Total direct and indirect cost for HF is expected to more than double between 2012 and 2030; however, little is known how new therapies, such as sacubitril/valsartan (S/V), may impact patient (pt) paid costs. Objective To compare pt paid h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db3d7f26a8b845dab526954df4903769
https://doi.org/10.1016/j.cardfail.2018.07.079
https://doi.org/10.1016/j.cardfail.2018.07.079
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 3:204-211
Background— Current guidelines emphasize the need for optimal medical therapy before implantation of cardiac devices (implantable cardioverter-defibrillator, cardiac resynchronization therapy). Our objective was to evaluate use of β-blockers (BB)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d535adf0279f5c66decf42e75996769
https://doi.org/10.1161/circoutcomes.109.880450
https://doi.org/10.1161/circoutcomes.109.880450
Publikováno v:
Clinical Pediatrics. 49:485-490
Objective. To evaluate the prevalence of atypical antipsychotic use in privately insured children and the diagnoses associated with treatment. Study design. Claims were used to conduct a retrospective cohort study of children aged 2 through 18 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cd861a4c0dca8176fdeb746f29d0c26
https://doi.org/10.1177/0009922809347369
https://doi.org/10.1177/0009922809347369